Tumor Biology

, Volume 37, Issue 5, pp 6551–6559 | Cite as

Expression and clinical implication of S100A12 in gastric carcinoma

  • Dan Li
  • Zhi Zeng
  • Tao Yu
  • Jian Qin
  • Jie Wu
  • Jin-Chun Song
  • Zi-Ying Zhou
  • Jing-Ping Yuan
Original Article
  • 184 Downloads

Abstract

S100 protein family has been implicated in multiple stages of tumorigenesis and progression in which S100A12 is one of the subtypes. However, the role of S100A12 in gastric carcinoma (GC) has not been elucidated yet. This study was aimed to investigate the expression of S100A12 in GC tissues and evaluate the clinical significance of S100A12 in GC patients. S100A12 protein was detected in 207 GC and 52 paired non-cancerous mucosal tissues by immunohistochemistry, while messenger RNA (mRNA) was investigated by Oncomine database analysis. Moreover, survival analysis was performed and the correlation between S100A12 and ubiquitin-specific protease 10 (USP10) and p53 was determined. As for tumor cells, the expression of S100A12 protein and mRNA in GC was proved to be lower than that in non-cancerous mucosa tissues (p < 0.05). Clinicopathological analysis showed that S100A12 protein was negatively associated with tumor size (p = 0.004), depth of invasion (p = 0.022), tumor node metastasis (TNM) stage (p = 0.018), Lauren classification (p < 0.000), and cell differentiation (p < 0.000). In contrast, a positive correlation was found between S100A12 and USP10 protein (p < 0.000). However, no relationship was detected between S100A12 and p53. Moreover, the survival analysis indicated that S100A12 protein was a favorable factor of prognosis of GC (p < 0.05). Although the expression of S100A12 in the stromal cells was detected higher than that in the tumor cells, no relationship between S100A12 protein in stromal cells and the clinicopathological features described above was found (p > 0.05). Our findings suggested that low expression of S100A12 might be served as a new marker in the tumorigenesis and progression of GC.

Keywords

S100A12 Gastric carcinoma USP10 Clinical implication 

Notes

Acknowledgments

This work was supported by grants from independent scientific research subject for young teachers of Wu Han University (Grant No. 2042014kf0131) and (Grant No. 2042015kf0076).

Compliance with ethical standard

Conflicts of interest

None

References

  1. 1.
    Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res. 2014;4(2):89–115.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, et al. Functions of S100 proteins. Curr Mol Med. 2013;13(1):24–57.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Nasser MW, Elbaz M, Ahirwar DK, Ganju RK. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins. Cancer Lett. 2015;365(1):11–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Gross SR, Sin CG, Barraclough R, Rudland PS. Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci. 2014;71(9):1551–79.CrossRefPubMedGoogle Scholar
  5. 5.
    Robinson MJ, Hogg N. A comparison of human S100A12 with MRP-14 (S100A9). Biochem Biophys Res Commun. 2000;275(3):865–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Hsu K, Champaiboon C, Guenther BD, Sorenson BS, Khammanivong A, Ross KF, et al. Anti-infective protective properties of s100 calgranulins. Antiinflamm Antiallergy Agents Med Chem. 2009;8(4):290–305.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Meijer B, Gearry RB, Day AS. The role of S100A12 as a systemic marker of inflammation. Int J Inflamm. 2012;2012:907078.CrossRefGoogle Scholar
  8. 8.
    Hofmann BM, Schmidt AM. S100/calgranulins EN-RAGEing the blood vessels: implications for inflammatory responses and atherosclerosis. Am J Cardiovasc Dis. 2011;1(1):92–100.Google Scholar
  9. 9.
    Wittkowski H, Sturrock A, van Zoelen MA, Viemann D, van der Poll T, Hoidal JR, et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med. 2007;35(5):1369–75.CrossRefPubMedGoogle Scholar
  10. 10.
    Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis. 2014;20(9):1668–77.CrossRefPubMedGoogle Scholar
  11. 11.
    Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(4):742–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Pac-Kozuchowska E, Krawiec P, Mroczkowska-Juchkiewicz A. Fecal lactoferrin in identifying and management of inflammatory bowel disease. Pol Merkur Lekarski. 2014;37(217):61–4.PubMedGoogle Scholar
  13. 13.
    Hofmann BM, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, et al. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res. 2010;106(1):145–54.CrossRefGoogle Scholar
  14. 14.
    Geczy CL, Chung YM, Hiroshima Y. Calgranulins may contribute vascular protection in atherogenesis. Circ J. 2014;78(2):271–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Funk S, Mark R, Bayo P, Flechtenmacher C, Grabe N, Angel P, et al. High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma. Int J Cancer. 2015;136(9):2037–46.CrossRefPubMedGoogle Scholar
  16. 16.
    Thierolf M, Hagmann ML, Pfeffer M, Berntenis N, Wild N, Roessler M, et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin Appl. 2008;2(1):11–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhao Y, Zhang TB, Wang Q. Clinical significance of altered S100A2 expression in gastric cancer. Oncol Rep. 2013;29(4):1556–62.PubMedGoogle Scholar
  19. 19.
    Liu YF, Liu QQ, Wang X, Luo CH. Clinical significance of S100A2 expression in gastric cancer. Tumour Biol. 2014;35(4):3731–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang Q, Zhu M, Cheng W, Xing R, Li W, Zhao M, et al. Downregulation of 425G > a variant of calcium-binding protein S100A14 associated with poor differentiation and prognosis in gastric cancer. J Cancer Res Clin Oncol. 2015;141(4):691–703.CrossRefPubMedGoogle Scholar
  21. 21.
    Ling Z, Li R. Clinicopathological and prognostic value of S100A4 expression in gastric cancer: a meta-analysis. Int J Biol Markers. 2014;29(2):99–111.CrossRefGoogle Scholar
  22. 22.
    Zeng Z, Wu HX, Zhan N, Huang YB, Wang ZS, Yang GF, et al. Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumour Biol. 2014;35(4):3845–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Cui J, Chen Y, Chou WC, Sun L, Chen L, Suo J, et al. An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Res. 2011;39(4):1197–207.CrossRefPubMedGoogle Scholar
  24. 24.
    Wafer LN, Tzul FO, Pandharipande PP, McCallum SA, Makhatadze GI. Structural and thermodynamic characterization of the recognition of the S100-binding peptides TRTK12 and p53 by calmodulin. Protein Sci. 2014;23(9):1247–61.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhang J, Zhang K, Jiang X, Zhang J. S100A6 as a potential serum prognostic biomarker and therapeutic target in gastric cancer. Dig Dis Sci. 2014;59(9):2136–44.CrossRefPubMedGoogle Scholar
  26. 26.
    Tanaka M, Ichikawa-Tomikawa N, Shishito N, Nishiura K, Miura T, Hozumi A, et al. Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion. BMC Cancer. 2015;15:53.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Leclerc E, Heizmann CW. The importance of Ca2+/Zn2+ signaling S100 proteins and RAGE in translational medicine. Front Biosci (Schol Ed). 2011;3:1232–62.Google Scholar
  28. 28.
    Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15(2):96–109.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ji YF, Huang H, Jiang F, Ni RZ, Xiao MB. S100 family signaling network and related proteins in pancreatic cancer (review). Int J Mol Med. 2014;33(4):769–76.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Dan Li
    • 1
  • Zhi Zeng
    • 2
  • Tao Yu
    • 3
  • Jian Qin
    • 4
  • Jie Wu
    • 1
  • Jin-Chun Song
    • 1
  • Zi-Ying Zhou
    • 2
  • Jing-Ping Yuan
    • 2
  1. 1.Department of PharmacyRenmin Hospital of Wuhan UniversityWuhanChina
  2. 2.Department of PathologyRenmin Hospital of Wuhan UniversityWuhanChina
  3. 3.Integrated Traditional Chinese and Western Medicine Ward of Oncology Department, the Central Hospital of Wuhan, Tongji Medical CollegeHuazhong University of Science and TechonologyWuhanChina
  4. 4.Central LaboratoryRenmin Hospital of Wuhan UniversityWuhanChina

Personalised recommendations